Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS
· Delayed Price · Currency is USD
0.121
+0.001 (0.83%)
Dec 3, 2024, 4:00 PM EST
PVCT Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.72 | 0.56 | 0.99 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 20.36% | -43.61% | - | - | - | - | Upgrade
|
| Cost of Revenue | 1.81 | 1.7 | 2.31 | 2.52 | - | - | Upgrade
|
| Gross Profit | -1.09 | -1.14 | -1.32 | -2.52 | - | - | Upgrade
|
| Selling, General & Admin | 1.08 | 1.36 | 1.55 | 2.12 | 2.21 | 2.37 | Upgrade
|
| Research & Development | - | - | - | - | 2.72 | 3.8 | Upgrade
|
| Operating Expenses | 1.08 | 1.36 | 1.55 | 2.12 | 4.94 | 6.17 | Upgrade
|
| Operating Income | -2.17 | -2.5 | -2.87 | -4.64 | -4.94 | -6.17 | Upgrade
|
| Interest Expense | -0.24 | -0.22 | -0.16 | -0.96 | -1.75 | -1.46 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0 | 0.02 | Upgrade
|
| EBT Excluding Unusual Items | -2.41 | -2.71 | -3.03 | -5.6 | -6.68 | -7.6 | Upgrade
|
| Legal Settlements | -0.62 | -0.39 | -0.52 | - | - | 0.68 | Upgrade
|
| Other Unusual Items | - | - | - | 0.06 | 0 | - | Upgrade
|
| Pretax Income | -3.03 | -3.1 | -3.55 | -5.54 | -6.68 | -6.92 | Upgrade
|
| Net Income | -3.03 | -3.1 | -3.55 | -5.54 | -6.68 | -6.92 | Upgrade
|
| Net Income to Common | -3.03 | -3.1 | -3.55 | -5.54 | -6.68 | -6.92 | Upgrade
|
| Shares Outstanding (Basic) | 420 | 420 | 419 | 408 | 393 | 387 | Upgrade
|
| Shares Outstanding (Diluted) | 420 | 420 | 419 | 408 | 393 | 387 | Upgrade
|
| Shares Change (YoY) | 0.03% | 0.01% | 2.76% | 3.81% | 1.72% | 1.11% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | Upgrade
|
| Free Cash Flow | -2.93 | -2.57 | -3.04 | -1.01 | -4.09 | -6.19 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 | -0.02 | Upgrade
|
| Gross Margin | -150.69% | -204.69% | -133.60% | - | - | - | Upgrade
|
| Operating Margin | -299.98% | -447.97% | -290.12% | - | - | - | Upgrade
|
| Profit Margin | -418.37% | -556.16% | -359.41% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -405.20% | -461.17% | -307.52% | - | - | - | Upgrade
|
| EBITDA | -2.16 | -2.49 | -2.86 | -4.63 | -4.69 | -5.48 | Upgrade
|
| EBITDA Margin | -298.75% | - | -289.01% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.24 | 0.69 | Upgrade
|
| EBIT | -2.17 | -2.5 | -2.87 | -4.64 | -4.94 | -6.17 | Upgrade
|
| EBIT Margin | -299.98% | - | -290.12% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.